BANK VONTOBEL/PUT/MODERNA/84/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 19:02:24 28/06/2024 BST | ||
| 0.141 EUR | +5.22% |
|
| Current month | +98.59% | ||
| 1 month | +156.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.141 | +5.22% |
| 27/06/24 | 0.134 | +3.88% |
| 26/06/24 | 0.129 | +104.76% |
| 25/06/24 | 0.063 | -7.35% |
| 24/06/24 | 0.068 | -2.86% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 07:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM7NMM |
| ISIN | DE000VM7NMM6 |
| Date issued | 29/12/2023 |
| Strike | 84 $ |
| Maturity | 20/09/2024 (82 Days) |
| Parity | 10 : 1 |
| Emission price | 0.97 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.23 € |
|---|---|
| Lowest since issue | 0.027 € |
| Spread | 0.012 € |
| Spread % | 7.74% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
